The SenzaGen Group is a fast-growing leader in the field of non-animal testing. Through ground-breaking innovations and scientific expertise that better reflect human biology, the Group advances and protects human health while contributing to the replacement of animal testing.
Group companies: SenzaGen, VitroScreen and ToxHub.
SenzaGen is listed on Nasdaq Stockholm (SENZA).
The SenzaGen Group supports companies in advancing non-animal safety and efficacy assessment across chemicals, cosmetics, medical devices and pharmaceuticals.
As a pioneer in non-animal testing, we also contribute to the development of new in vitro methods.
The SenzaGen Group includes, in addition to the operations in Sweden, two specialized companies.
Technology for innovation
Developing alternatives to animal models is crucial for both ethical and scientific reasons. By offering groundbreaking innovations that are better suited to reflect human biological reactions, the SenzaGen Group is helping drive the transition away from animal testing.
GLP compliant laboratories
GLP stands for Good Laboratory Practice and is a quality system of requirements and principles to assure the quality of non-clinical safety studies. What constitutes GLP is defined by the OECD for use as a global standard requirement to ensure high-quality and reliable results for product filings and regulatory approval.
Both SenzaGen and VitroScreen have fully GLP-certified lab operations. In addition, VitroScreen’s quality system is certified according to ISO 9001 and ISO 13485.
The core of the SenzaGen Group’s business revolves around innovative tests and services in non-animal safety and efficacy assessment. These solutions enable companies across industries to develop safer and more effective products while reducing reliance on animal testing.
As a result, the SenzaGen Group contributes to bringing safe, ethical and more sustainable products to market.
